Apogee Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Apogee Therapeutics, Inc. (APGE) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$85.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-10
- Apogee Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$85.85M.
- Apogee Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$74.11M.
- Apogee Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$69.39M.
- Apogee Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$65.02M.
- Apogee Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$255.84M.
- Apogee Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$182.15M.
- Apogee Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$83.98M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 5 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 8 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 11 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$85.85M 10-Q · filed 2026-08-10 | -$159.97M 10-Q · filed 2026-08-10 | -$229.35M derived: sum of 3 quarters · filed 2026-08-10 | -$294.37M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | -$74.11M 10-Q · filed 2026-05-11 | -$143.50M derived: sum of 2 quarters · filed 2026-05-11 | -$208.52M derived: sum of 3 quarters · filed 2026-05-11 | -$274.62M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | -$69.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$134.41M derived: sum of 2 quarters · filed 2026-03-02 | -$200.50M derived: sum of 3 quarters · filed 2026-08-10 | -$255.84M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | -$65.02M 10-Q · filed 2025-11-10 | -$131.12M derived: sum of 2 quarters · filed 2026-08-10 | -$186.46M 10-Q · filed 2025-11-10 | -$253.67M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-06-30 | -$66.10M 10-Q · filed 2026-08-10 | -$121.44M 10-Q · filed 2026-08-10 | -$188.65M derived: sum of 3 quarters · filed 2026-08-10 | -$237.67M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-03-31 | -$55.34M 10-Q · filed 2026-05-11 | -$122.56M derived: sum of 2 quarters · filed 2026-05-11 | -$171.57M derived: sum of 3 quarters · filed 2026-05-11 | -$205.39M derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | -$67.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$116.24M derived: sum of 2 quarters · filed 2026-03-02 | -$150.05M derived: sum of 3 quarters · filed 2026-03-02 | -$182.15M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | -$49.02M 10-Q · filed 2025-11-10 | -$82.83M derived: sum of 2 quarters · filed 2025-11-10 | -$114.93M 10-Q · filed 2025-11-10 | -$146.66M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | -$33.82M 10-Q · filed 2025-08-11 | -$65.91M 10-Q · filed 2025-08-11 | -$97.64M derived: sum of 3 quarters · filed 2026-03-02 | -$118.48M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | -$32.09M 10-Q · filed 2025-05-12 | -$63.83M derived: sum of 2 quarters · filed 2026-03-02 | -$84.67M derived: sum of 3 quarters · filed 2026-03-02 | -$103.55M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | -$31.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$52.58M derived: sum of 2 quarters · filed 2026-03-02 | -$71.46M derived: sum of 3 quarters · filed 2026-03-02 | -$83.98M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | -$20.84M 10-Q · filed 2024-11-12 | -$39.73M derived: sum of 2 quarters · filed 2024-11-12 | -$52.25M 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | -$18.89M 10-Q · filed 2024-08-12 | -$31.41M 10-Q · filed 2024-08-12 | |||||
| 2023-03-31 | -$12.53M 10-Q · filed 2024-05-13 | ||||||
| 2022-12-31 | -$39.78M 10-K · filed 2024-03-05 | ||||||
| 2022-09-30 | -$19.66M 10-Q · filed 2023-11-13 | -$21.47M derived: sum of 2 quarters · filed 2023-11-13 | -$25.78M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | -$1.82M 10-Q · filed 2023-08-28 | -$6.12M 10-Q · filed 2023-08-28 |